Pharmacogenetics, adverse drug reactions and public health

被引：20

作者：

Kollek, R ^{[1
]}

van Aken, J ^{[1
]}

Feuerstein, G ^{[1
]}

Schmedders, M ^{[1
]}

机构：

[1] Univ Hamburg, FSP Biotech Gesell & Umwelt, DE-20251 Hamburg, Germany

来源：

COMMUNITY GENETICS | 2006年 / 9卷 / 01期

关键词：

adverse drug reactions; pharmacogenetics; public health; testing;

D O I：

10.1159/000090693

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Adverse drug reactions (ADRs) are a major public health problem. Pharmacogenetic testing prior to drug treatment is supposed to considerably alleviate this problem. The state of pharmacogenetic development was assessed by a systematic literature review, supplemented by expert interviews. Analysis of three case examples revealed that - with the exception of thiopurine methyltransferase (TPMT) - studies are lacking which unambiguously prove the clinical value of pharmacogenetic testing. Testing can prevent some, but by far not all ADRs. Since it does not compensate for clinical monitoring, pharmacogenetics can be regarded as add-on technology, applied in addition to established methods. A non-representative, explorative survey conducted amongst members of the German Society of Laboratory Medicine revealed that the demand for testing is limited and has not increased much, although a certain increase is expected in the future. Copyright (C) 2006 S. Karger AG, Basel.

引用

页码：50 / 54

页数：5

共 22 条

[1] With your genes? Take one of these, three times a day [J].

Abbott, A .

NATURE, 2003, 425 (6960) :760-762

[2] The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment [J].

Brockmöller, J ;

Kirchheiner, J ;

Schmider, J ;

Walter, S ;

Sachse, C ;

Müller-Oerlinghausen, B ;

Roots, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :438-452

[3] Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy [J].

Colombel, JF ;

Ferrari, N ;

Debuysere, H ;

Marteau, P ;

Gendre, JP ;

Bonaz, B ;

Soulé, JC ;

Modgliani, R ;

Touze, Y ;

Catala, P ;

Libersa, C ;

Broly, F .

GASTROENTEROLOGY, 2000, 118 (06) :1025-1030

[4]

FEUERSTEIN G, 2003, ETHIK MED, V15, P77

[5]

Holtzman NA, 2003, PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS, P163, DOI 10.1002/047142613X.ch9

[6]

KOLLEK R, 2004, PHARMAKOGENETIK IMPL

[7] Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism [J].

Lerer, B ;

Segman, RH ;

Fangerau, H ;

Daly, AK ;

Basile, VS ;

Cavallaro, R ;

Aschauer, HN ;

McCreadie, RG ;

Ohlraun, S ;

Ferrier, N ;

Masellis, M ;

Verga, M ;

Scharfetter, J ;

Rietschel, M ;

Lovlie, R ;

Levy, UH ;

Meltzer, HY ;

Kennedy, JL ;

Steen, VM ;

Macciardi, F .

NEUROPSYCHOPHARMACOLOGY, 2002, 27 (01) :105-119

[8] Pharmacogenomic-guided drug development: Regulatory perspective [J].

Lesko L.J. ;

Woodcock J. .

The Pharmacogenomics Journal, 2002, 2 (1) :20-24

[9]

Mancinelli L, 2000, AAPS PHARMSCI, V2

[10] How to manage individualized drug therapy:: Application of pharmacogenetic knowledge of drug metabolism and transport [J].

Meisel, C ;

Roots, I ;

Cascorbi, I ;

Brinkmann, U ;

Brockmöller, J .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (09) :869-876

← 1 2 3 →